Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial

MLA

Martin Dirisamer, et al. “Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial.” Ophthalmologica, vol. 233, Dec. 2014, pp. 8–17. EBSCOhost, https://doi.org/10.1159/000369566.

APA

Martin Dirisamer, Paul Foerster, Anselm Kampik, Nicolas Feltgen, Armin Wolf, Rupert W. Strauss, Siegfried G. Priglinger, Thomas C. Kreutzer, Amelie Pielen, & Lars-Olof Hattenbach. (2014). Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial. Ophthalmologica, 233, 8–17. https://doi.org/10.1159/000369566

Chicago

Martin Dirisamer, Paul Foerster, Anselm Kampik, Nicolas Feltgen, Armin Wolf, Rupert W. Strauss, Siegfried G. Priglinger, Thomas C. Kreutzer, Amelie Pielen, and Lars-Olof Hattenbach. 2014. “Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial.” Ophthalmologica 233 (December): 8–17. doi:10.1159/000369566.